The Academy of Pharmaceutical Sciences

Pharmed Group

Web Extra: U.S. Attorney's criminal information The brothers, who ran Pharmed Group, a Doral-based medical supply company, are accused of defrauding Kendall Regional Medical Center through a purchase order ...

McKesson may be defending distribution turf by eyeing Uniprix, say analysts

North American pharmaceutical distributor McKesson may be trying to protect its turf from poachers by entering the retail pharmacy business through the purchase of two leading Quebec companies, industry ...

Big Pharma: What Safe Haven?

Pharmaceutical stocks have been rallying of late, buoyed by news of richly priced mergers, including Roche's $44 billion bid for Genentech on July 21 and the $7 billion offer by generic drugmaker Teva ...

Optimer to secure $12.2 million in financing

Optimer Pharmaceuticals has received commitments from selected investors to purchase an aggregate of 1.44 million shares of Optimer's common stock at a purchase price of $8.48 per share pursuant to an effective shelf registration statement.

Inion wins approval to market graft containment systems

Inion has received 510(k) marketing clearance from the FDA for its biodegradable graft containment systems for spinal fusion procedures.

Metabolon implements metabolomics platform at Pfizer

Metabolon has announced the implementation of its metabolomics technology at Pfizer's Bioprocess R&D Group.

Pawfect Foods acquires Synergy Pharmaceuticals

Pawfect Foods has acquired Synergy Pharmaceuticals in exchange for shares of its common stock issued to Callisto Pharmaceuticals. The company has also completed a $3 million private placement.

Cenix signs research agreement with Regulus Therapeutics

Cenix BioScience has signed a research agreement with Regulus Therapeutics to advance the latter's efforts in the discovery of novel therapeutic miRNA modulators.

Tekmira selects two products for clinical development in 2009

Tekmira Pharmaceuticals has selected ApoB Snalp and PLK1 Snalp as its two lead product candidates and plans to advance both into clinical development in 2009.

TeleHealth and Vocollect sign reseller agreement

Vocollect Healthcare Systems and TeleHealth Services have announced a strategic partnership, whereby TeleHealth will resell AccuNurse voice-assisted care to deliver broadened solutions for the needs of its customer base.

Alnylam grants new InterfeRx license to Calando

Alnylam Pharmaceuticals has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, a new target-specific InterfeRx license to discover, develop, and commercialize a synthetic siRNA directed toward an undisclosed cancer gene target.

American Laser Centers names new CIO

American Laser Centers, a provider of laser hair removal and other noninvasive aesthetic services, has appointed Christopher Eagle as its new chief information officer.

HealthTronics acquires UroPath

HealthTronics, a provider of urology services and products, has acquired UroPath, a provider of anatomical pathology laboratory services, for $7.5 million.

Allos initiates enrollment for Phase II bladder cancer trial

Allos Therapeutics has started patient enrollment in a Phase II, open-label, single-arm, multi-center study of pralatrexate in patients with advanced or metastatic relapsed transitional cell carcinoma of the urinary bladder.

Curis selects new development candidate from cancer drug platform

Curis has selected an orally available, synthetic small molecule inhibitor of heat shock protein 90 as a development candidate from its targeted cancer drug development platform.

Provectus initiates recruitment for Phase II cancer trial

Provectus Pharmaceuticals has initiated recruitment for a Phase II clinical trial of its lead oncology agent PV-10 at the MD Anderson Cancer Center, in Houston, Texas.

Rexahn receives patent for new cancer compounds

Rexahn Pharmaceuticals has announced that the US Patent & Trademark Office has issued patent for new cancer compounds.

Osmetech wins approval for warfarin sensitivity test

Osmetech has received 510(k) clearance from the FDA for its eSensor warfarin sensitivity test to be used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug, warfarin.

Santarus to promote Depomed's Glumetza prescription products

Santarus and Depomed have entered into a promotion agreement granting Santarus exclusive rights to promote Depomed's Glumetza prescription products in the US.

Tranzyme receives notices of allowance for two new patents

Tranzyme Pharma has received notices of allowance from the US Patent and Trademark Office for two patent applications entitled 'Macrocyclic modulators of the ghrelin receptor' and 'Spatially-defined macrocyclic compounds useful for drug discovery'.

CardioNet announces public offering of common stock

CardioNet, a wireless medical technology company, has announced an underwritten public offering of 4.66 million shares of common stock by certain of the company's existing stockholders.

Astellas and Boehringer file patent infringement lawsuit against Impax

Astellas pharma and Boehringer Ingelheim Pharmaceuticals have jointly filed a patent infringement lawsuit in the US against Impax laboratories regarding its submission of an abbreviated new drug application for a generic version of Astella's tamulosin hydrochloride capsules.

US NIAID not to go ahead with HIV vaccine trial

The US National Institute of Allergy and Infectious Diseases, part of the NIH, has cancelled a large Phase IIb study planned for the development of a novel HIV vaccine. In its place the institute intends to begin a smaller study, according to Scrip World Pharmaceutical News.

Dr. Flemming Ornskov Nominated for Election as Chairman of the Supervisory Board of Evotec

Evotec AG announced today that at its July 9, 2008 meeting the Supervisory Board of Evotec AG decided to propose the election of Dr.

Minority-owned company alleges health care firm used its status to obtain contracts

A small Chicago-based minority-owned promotional products and print company and its owner sued health care products and services giant Cardinal Health Inc.

Akesis names new board member

Akesis Pharmaceuticals, a metabolic disease drug development company, has appointed Christos Mantzoros to its scientific advisory board.

MMRC initiates Phase I/II myeloma trial

The Multiple Myeloma Research Consortium has initiated a Phase I/II study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Velcade for Injection for the treatment of relapsed multiple myeloma.

Dor BioPharma and Steward Cross sign collaborative agreement

Dor BioPharma has entered into collaboration with Steward Cross, a specialty pharmaceutical company based in Singapore, under which Steward Cross will act as Dor's sponsor with regard to the administration of a Named Patient Access Program for orBec to patients suffering from acute gastrointestinal graft-versus-host disease in Singapore and Malaysia.

BMP Sunstone to acquire Shengda Pharmaceutical

BMP Sunstone has announced that its wholly-owned subsidiary, Sunstone Pharmaceutical, has signed a non-binding letter of intent to acquire 75% of Zhangjiakou Shengda Pharmaceutical, Zhangjiakou Pharmaceutical Group for up to RMB30 million.

OtisMed relocates headquarters

OtisMed, an orthopedic technology company, has tripled the size of its operations with the move to a new, 28,608 square foot facility in Alameda, California.

Qtrac Software signs partnership with Patient Placement Systems

Qtrac Software and Patient Placement Systems, a provider of patient referral software, have announced a partnership to help long term care facilities efficiently manage patient referrals and intake and seamlessly transition to an electronic health record designed to deliver quality of care.

Instead Healthcare and Health Sciences sign distribution agreement

Instead Healthcare has signed a joint venture agreement with Hong Kong-based Health Sciences for the launch and distribution throughout the Asia Pacific region of its unique, patented feminine hygiene product, Instead Softcup.

Omnicell launches new wireless supply mobile cart

Omnicell has introduced its medical grade wireless supply mobile cart that allows clinicians to access specialty supplies quickly, securely and efficiently from any location at any time.

AcuNetx's president and CEO resigns

AcuNetx, a provider of diagnostic, analytical and therapeutic tools for the medical community, has announced that it had accepted the resignation of Ronald Waldorf, president and CEO of the company.

PharmEng granted site license from Health Canada

PharmEng International has announced that its wholly owned subsidiary, Keata Pharma, has received a site license issued by the Minister of Health under the authority of the Natural Health Products Regulations for the manufacturing, packaging and labeling of natural health products at its manufacturing facility located in Sydney, Nova Scotia.

Allergan and Jan Marini to settle patent infringement suit

Allergan has agreed to dismiss its legal action against Jan Marini Skin Research, one of the defendants in Allergan's patent infringement lawsuit pending in the US District Court of California.

Agfa HealthCare wins new contract from Premier Purchasing Partners

Agfa HealthCare has received a new three-year contract from Premier Purchasing Partners, to provide film and medical imagers at competitive terms and conditions to the healthcare alliance's 2,000 member hospitals and 53,000 other alternate healthcare sites in the US.

Velcura names new board member

Michigan-based biotechnology company Velcura Therapeutics has appointed William Brinkerhoff to its board of directors.

minSURG establishes new international division

minSURG, producers of the TruFUSE percutaneous facet stabilization procedure, has announced the creation of minSURG International, Incorporated.

ProtAffin wins orphan designation for anti-inflammatory drug

ProtAffin has received orphan medicinal product designation in the EU from the European Medicines Evaluation Agency for its lead product PA401.

Sanofi-Aventis terminates commercialization agreement with Taiho

Sanofi-Aventis has announced that it is returning its territory rights to Japan-based Taiho Pharmaceutical for the development and commercialization of the oral anticancer agent S-1.

Sanofi-Aventis signs collaborative agreement with Johns Hopkins University

Sanofi-Aventis has signed a three year agreement with the division of allergy and clinical immunology of the Johns Hopkins University School of Medicine, Baltimore, Maryland.

Invitrogen and Active Motif join hands in gene analysis

Invitrogen and Active Motif have announced a joint project to explore the use of field programmable gate array technology for the analysis of next-generation sequencing data.

Roche to acquire all outstanding shares of Genentech

Roche has proposed to acquire the outstanding publicly held interest in Genentech for $89 per share in cash, or a total payment of approximately $43.7 billion to equity holders of Genentech other than Roche.

Advanced Bionics settles financial suit with FDA

Advanced Bionics has agreed to settle an administrative complaint arising from a disagreement with the FDA.

Teva buys Barr Pharmaceuticals: The price tag reached $7.46 billion....

Teva buys Barr Pharmaceuticals: The price tag reached $7.46 billion. Teva will also assume about $1.5 billion of Barr debt.

Drug deals and soaps

In what looks like the perfect prescription for growth, Teva Pharmaceutical is buying rival generic drugmaker Barr Pharmaceuticals Inc .

Teva to buy Barr Pharma for more than $7 billion

Israel-based Teva Pharmaceutical Industries Ltd . said acquiring Montvale, N.J.-based Barr Pharmaceuticals Inc ., the world's No.

ClinicAid and Quartesian Launch Joint CRO Venture Clinesian

ClinicAid Research Management and Quartesian today announced formation of a joint venture company, Clinesian.

Teva Enrolls Patients For A Second Large Global Phase III Trial Of Oral Laquinimod

Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced that patients are being enrolled for the BRAVO Phase III pivotal trial.

Duramed parent Barr Pharmaceuticals to be acquired by Teva

In addition, Teva will assume about $1.5 billion of Barr's debt. Teva and Barr said in a news release that the combined company will employ 37,000 worldwide, with operations in more than 60 countries.

Winner Medical granted patent approval for PurCotton production method

Winner Medical Group has announced that its method for producing PurCotton products has received a patent from the US Patent and Trademark Office.

Thermo Fisher Scientific acquires Affinity BioReagents

Thermo Fisher Scientific has acquired Affinity BioReagents, a provider of antibodies, peptides, proteins and other reagents for life science research, based in Golden, Colorado.

OptiMedica names new CFO

US based ophthalmic company OptiMedica, has appointed Mark Murray as its new CFO.

Meditrina wins approval for Phase IIb endometriosis trial

Meditrina Pharmaceuticals has announced the approval of its second investigational new drug application for a Phase IIb dose ranging clinical trial to study MPI-676, the company's aromatase inhibitor, in combination with estrogen and progestin for the treatment of endometriosis.

Medtronic acquires Restore Medical

Medtronic, a medical technology company, has acquired Restore Medical, which develops invasive medical devices for the effective treatment of chronic snoring, obstructive sleep apnea and other sleep breathing disorders.

Intertrade Dental to distribute Zila's cancer screening products

Zila has selected Intertrade Dental to be the exclusive distributor of ViziLite Plus with TBlue, Zila's oral cancer screening product, in Greece and Cyprus.

Advanced Life Sciences and UK Ministry of Defence announce collaboration

Advanced Life Sciences Holdings has announced that the UK's Defence Science and Technology Laboratory will evaluate the developmental compound ALS-886 as a treatment for chemically induced lung injury.

MacroGenics acquires Raven Biotechnologies

MacroGenics has acquired California-based Raven Biotechnologies, which focuses on the discovery and development of monoclonal antibody therapeutics for oncology through its cancer stem cell program.

Anesiva initiates Phase II study of pain drug

Anesiva has initiated a Phase II clinical trial of Adlea, a long-acting, site specific, non-opioid drug candidate for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

China Medicine granted new Australian patent

China Medicine has received a patent from the Australia Patent Office for recombinant aflatoxin detoxifizyme. The patent is valid through January 13, 2025.

Isis names new vice president and CMO

Isis Pharmaceuticals has appointed Martin Bedigian as its new vice president and chief medical officer, effective August 18, 2008.

Schering-Plough wins Japanese marketing approval for Nasonex

Schering-Plough has announced that Schering-Plough KK, the company's country operation in Japan, has received marketing approval for Nasonex nasal spray 50mcg for the treatment of allergic rhinitis in adult patients.

Dynova Laboratories acquires SiCap Industries

Dynova Laboratories, a natural products company, has acquired SiCap Industries and its innovative line of capsaicin-based products marketed under the Sinus Buster brand.

Misonix granted approval for Sonatherm tissue ablation system

Misonix has received 510(k) clearance from the FDA to market its Sonatherm 600i high intensity focused ultrasound soft tissue ablation system in the US.

Genzyme and PTC collaborate on genetic disorder drug

Genzyme and PTC Therapeutics have announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations.

3M Health Care and Greystone sign licensing agreement

3M Health Care and Greystone Pharmaceuticals have entered into an exclusive, worldwide license agreement for wound care products using Greystone's patented polyhydrated ionogens technology, a proprietary formulation that aids in the management of hard-to-heal wounds.

Calibrant signs R&D agreement with AFIP

Calibrant Biosystems has signed a cooperative R&D agreement with the Armed Forces Institute of Pathology to explore the use of the company's Gemini proteomics technology in the discovery and development of novel protein biomarkers.

Impliant introduces new version of Tops spine system

Impliant has conducted the first surgery in the US using a less-invasive version of its Tops system, a total posterior arthroplasty device designed to treat spinal stenosis with or without facet arthrosis and spondylolisthesis.

Cimex wins German approval for Clopidogrel

Cimex has received approval from the Federal Institute for Drugs and Medical Devices, Germany for clopidogrel and has transferred it to its marketing partners.

National Stem Cell to launch new cosmoceuticals line

National Stem Cell Holding has announced that its wholly owned subsidiary Proteoderm, will introduce the company's first commercial line of cosmoceuticals, which will be sold through medical sales representatives for use by dermatologists, plastic surgeons and other licensed health care professionals.

Drug Stocks Mixed; Barr Soars On Takeover Talk

Real yields have curves; unless, of course, it's a flat yield curve. The yield curve is exactly that: a curved line on a graph that plots the interest rates of several bonds with different maturity dates, ...

Pakistan government blocks proposal to import Indian drugs

Mumbai: The Pakistan government has blocked a proposal to import 400 medicines from India, following intense lobbying by local pharmaceutical industry.

More People Sign Up for Jobless Benefits in U.S.

The Labor Department reported Thursday that new applications filed for unemployment insurance increased by a seasonally adjusted 18,000 to 366,000 for the week ending July 12.

Is Teva Looking to Buy Barr Pharmaceuticals?

Rumors are swirling in the Israeli press , that the world's largest generic drug maker is about to become much larger.

Smiths Medical wins multi year contract from HealthTrust

Smiths Medical, part of Smiths Group's global technology business, has received a multi year contract from HealthTrust Purchasing Group.

Novartis extends RNAi therapeutics collaboration with Alnylam

Alnylam Pharmaceuticals has announced that Novartis has elected to extend the company's RNAi therapeutics collaboration for an additional year, through October 2009.

Dendreon initiates Phase II prostate cancer trial

Dendreon has initiated a Phase II trial of Provenge, its investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy.

China Medical acquires distribution rights to macular degeneration drug

China Medical System Holdings has reached an agreement with its marketing partner, Ophol, to gain full control of distributing Augentropfen Stulln Mono in China.

Theragenics to acquire NeedleTech Products

Theragenics has signed an agreement to acquire NeedleTech Products for $47.8 million in cash, subject to adjustment. The acquisition is expected to close in the third quarter of 2008.

EpiCept and GNI join hands to develop hepatitis drug in Asia

GNI and EpiCept have reached an agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis.

Optimer reports positive results from Phase III diarrhea trial

Optimer Pharmaceuticals has announced positive results from its first double-blind Phase III trial assessing the safety and efficacy of Prulifloxacin as a once-daily, three-day oral therapy for infectious diarrhea.

Symphogen and Biovitrum recruit first patient for Phase II ITP study

Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients.

Iris receives purchase order from Kuwait Ministry of Health

Iris International has announced that its Middle East distributor, Bader Sultan & Bros has received an order from the Kuwait Ministry of Health for seven iQ200 Elite automated urine microscopy analyzers.

Generex obtains purchase order from distributor in Saudi Arabia

Generex Biotechnology has received a purchase order for the approximate amount of $300,000 through its Generex MENA from a distributor in Saudi Arabia.

Immunosyn announces proposed agreements for distribution of autoimmune drug

Immunosyn has announced that the distribution of SF-1019 in the State of Utah is anticipated to begin shortly through Renewed Hope Clinic in Beaver, Utah.

Omnicare acquires Advanced Care Scripts

Omnicare, a provider of pharmaceutical care for the elderly, has acquired Advanced Care Scripts, a provider of specialty pharmaceutical services.

Galderma wins Japanese approval for Differin gel 0.1%

Galderma Pharma has announced that Japan's Ministry of Health, Labor and Welfare has approved Differin gel 0.1%, a novel topical treatment for acne vulgaris in Japan.

Bioenergy appoints new CEO

US based integrative life science company Bioenergy has named Raj Khankari as its new CEO, effective August 1, 2008.

Alverix names new president and CEO

Alverix, an optoelectronics company developing portable medical diagnostic instruments, has appointed James Merselis as its new president and CEO.

Misonix signs new distribution agreement with Intermedica

Misonix has signed a new, three year, exclusive distribution agreement with privately-held Intermedica of Nizhny Novgorod, Russia for the distribution of the Sonablate 500 high intensity focused ultrasound system.

Huifeng signs strategic alliance with Premier Media Service

Huifeng Bio-pharmaceutical Technology has established a strategic alliance with Premier Media Service of Mesa, Arizona.

Bellus Health to acquire Innodia

Bellus Health has signed a definitive agreement to purchase capital stock of Innodia, which engages in developing compounds for the treatment of diabetes, obesity and related metabolic conditions and diseases.

Asubio's Biopten wins approval for additional indication

Asubio Pharma, one of the group companies of Daiichi Sankyo, has announced an additional indication for the inherited metabolic disease agent Biopten for the treatment of tetrahydrobiopterin responsive hyperphenylalaninemia.

BG Medicine secures $40 million in series D financing

BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics, has raised $40 million in its series D financing.

Import of Indian drugs blocked by Pak govt

Pakistan government has blocked a proposal for importing 400 medicines from India following intense lobbying against the move by the local pharmaceutical industry.

Pharma cuts down its sales force

The major drug makers are restructuring their sales force by cutting down jobs and other marketing costs in a bid to save money and reconfigure business, according to FiercePharma.

Roche Pharma suspended from body

The ban is in connection with breaches of its code of practice, the ABPI said. It relates to activities between 2003 and 2005, including actions held to bring discredit on, or cut confidence in, the ...

Wyeth, Impax get court approval of Effexor patent suit settlement

Wyeth and Impax Laboratories Inc. said late Wednesday the companies' settlement of their patent infringement lawsuit related to Impax's generic version of Wyeth's Effexor XR has received court approval.

Spineology raises $7.5 million in financing

Spineology, a provider of minimally invasive spinal surgery devices, has closed on $7.5 million financing.

Nutrition 21 names new president and CEO

Nutrition 21, a provider of chromium picolinate-based and omega-3 fish oil-based supplements, has appointed Michael Zeher as its new president and CEO and as a member of the board.

Medtronic wins Japanese approval for Reveal DX cardiac monitor

Medtronic has received Japanese regulatory approval for the Reveal DX insertable cardiac monitor.

Ingenuity Systems and CHDI sign multi-year deal

Ingenuity Systems, a provider of information solutions for life science researchers, and CHDI Foundation have announced a multi-year agreement for CHDI to use IPA as a platform to integrate Ingenuity-curated information relevant to Huntington's disease.

Rib-X initiates Phase II skin infection trial

Rib-X Pharmaceuticals has initiated a Phase II clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated skin and skin structure infections.

Abeome and Cato Research to collaborate on ovarian cancer drug

Abeome has announced a strategic equity investment by Cato BioVentures and collaboration with Cato Research, its global contract R&D organization.

MedX signs distribution agreement with Technology4Medicine

MedX Health has signed an exclusive distribution agreement with Technology4Medicine, a newly formed laser company based in San Clemente, California, for the US dental, dermatology, plastic surgery and anti-aging markets.

Remedi SeniorCare acquires HealthCare Pharmacy

Remedi SeniorCare, a provider of pharmacy services for senior healthcare facilities, has acquired HealthCare Pharmacy of Covington, Ohio.

InTouch Health signs collaboration agreement with Genentech

InTouch Technologies, doing business as InTouch Health, has entered into a memorandum of agreement with Genentech, to facilitate Activase education for its growing telestroke customer base.

Metabolon expands multi-study agreement with Mitsubishi Tanabe

Metabolon has announced the continuation and expansion of a multi-study agreement with Mitsubishi Tanabe Pharma, a global and research-driven pharmaceutical company.

Wyeth to acquire ThermaCare from Procter & Gamble

Wyeth Consumer Healthcare, a division of Wyeth, has signed an agreement to purchase ThermaCare, an over-the-counter heat wrap, from Procter & Gamble. The transaction is expected to close within the next few months.

Alfacell signs Onconase distribution agreement with Megapharm

Alfacell has entered into a distribution agreement with Megapharm for the commercialization of Onconase in Israel.

Dor BioPharma signs collaboration agreement with IDIS

Dor BioPharma has executed a definitive collaborative agreement with IDIS, for the supply and distribution within the EU of the company's investigational drug orBec for the treatment of gastrointestinal graft-versus-host disease via a named patient program.

Draximage to market Neoprobe's Lymphoseek in Europe

Neoprobe and Draximage, a division of Draxis Specialty Pharmaceuticals, have executed a non-binding letter of intent, whereby Draximage would market and distribute Lymphoseek on an exclusive basis in the EU, Switzerland, Scandinavia, Turkey, Canada and India.

Duke University Hospital acquires TraumaCad from Orthocrat

Orthocrat has announced that Duke University Hospital, in Durham, North Carolina, has purchased TraumaCad.

Medicago to conduct feasibility study for vaccine facility in France

Medicago has announced that it will conduct a feasibility study in collaboration with Genopole biopark, in Evry, for the establishment of a vaccine production facility in France.

Dyax enters negotiation period with Dompe for angioedema drug

Dyax has entered into an exclusive negotiation period ending on September 30, 2008 with Dompe Farmaceutici for a European license to DX-88 in angioedema indications, including hereditary angioedema, for which the company recently completed its second Phase III trial.

ViroPharma to acquire Lev Pharmaceuticals

ViroPharma and Lev Pharmaceuticals have signed a definitive merger agreement under which ViroPharma will acquire Lev for $442.9 million of upfront consideration, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock.

EyeGate initiates dosing in Phase II uveitis trial

EyeGate Pharma has initiated patient dosing in a prospective, multi-center, randomized, double-masked US Phase II proof-of-concept study of the EyeGate II ocular drug delivery system.

Mylan Inc. sued over painkilling patch deaths

Survivors of three people who overdosed on a painkilling patch are suing generic drug producer Mylan Inc.

Roxane wins approval for Morphine sulfate tablets and oral solution

Roxane Laboratories has received the FDA approval for its new drug application for Morphine sulfate tablets and oral solution CII.

RxElite signs supply and marketing agreement with Hi-Tech Pharmacal

RxElite has signed a 10 year development, supply and marketing agreement with Hi-Tech Pharmacal, a manufacturer and marketer of liquid generic products.

ThermoGenesis granted approval to market MarrowXpress

ThermoGenesis has received authorization from the FDA to begin marketing its MarrowXpress device for use in a clinical laboratory setting or intraoperatively for preparation of a cell concentrate from bone marrow.

DiaMedica's Phase II diabetes trial meets end point

DiaMedica has reported top-line results of a Phase II trial showing that its investigational drug DM-83 met the primary endpoint by lowering peak insulin levels in diabetic patients.

SurModics's subsidiary licenses nanoparticle technology from PharmaSol

SurModics has announced that its Brookwood Pharmaceuticals subsidiary has licensed lipid nanoparticle technology from PharmaSol of Berlin, Germany.

Noven names new vice president and CMO

Noven Pharmaceuticals has appointed Joel Lippman as its new vice president of clinical development and chief medical officer, effective immediately.

Amgen reports positive results for treatment of bone loss in cancer study

Amgen has reported positive results from a three-year pivotal Phase III placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.

SyntheMed wins Canadian approval for Repel-CV

SyntheMed has announced that Repel-CV, the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart surgery.

Theravance reports encouraging results from Phase I COPD trial

Theravance has announced the positive results from a Phase I study designed to assess the safety, tolerability and pharmacokinetics of an investigational inhaled long-acting muscarinic antagonist, GSK1160724/TD-4208, for the treatment of chronic obstructive pulmonary disease.

Spherix to expand Phase III diabetes trial

Spherix has reported that the Phase III clinical trial of its potential type 2 diabetes drug, Naturlose, will expand outside of the US.

IHSI acquires two operating subsidiaries from HealthSonix

Innovative Health Sciences has acquired two operating subsidiaries, HealthSonix Medical and AquaSonix Therapy Canada from HealthSonix in exchange for 35.36 million common shares of IHSI.

Synta appoints new senior vice president and CCO

Synta Pharmaceuticals has appointed Michael Bailey as its new senior vice president and chief commercial officer. Mr Bailey will join Synta on August 4, 2008.

Gene Logic renews agreement with Agilent Technologies

Gene Logic and Agilent Technologies have announced that Gene Logic has been reappointed as a certified microarray service provider for Agilent gene expression microarrays.

MitoSciences signs new agreement with Hospital for Sick Children, Canada

MitoSciences has signed an agreement with the Hospital for Sick Children in Toronto, Canada, whereby SickKids will provide MitoSciences with recombinant vector systems for producing the four kinases and two phosphatases that activate and deactivate the enzyme pyruvate dehydrogenase.

Cardiome reports positive results from Phase II atrial fibrillation study

Cardiome Pharma has announced positive clinical results from its 90-day Phase IIb study of vernakalant. The final analysis demonstrated statistically significant efficacy for the patient group receiving 500mg bid of vernakalant as compared to placebo.

Luminex signs licensing agreement with ViroNovative

Luminex and ViroNovative have signed a licensing agreement that gives Luminex worldwide rights to use ViroNovative's human metapneumovirus intellectual property in the xTAG respiratory viral panel.

Allergan acquires Aczone gel from QLT

Allergan Sales, a wholly-owned subsidiary of Allergan, and QLT USA, a wholly-owned subsidiary of QLT, have announced the completion of Allergan's acquisition of QLT's Aczone gel 5% product, a topical treatment for acne vulgaris.

WellPoint expands partnership with CareNex Health Services

WellPoint has expanded its strategic partnership position with CareNex Health Services to help promote quality care and service for infants experiencing clinically-complex health issues, and their families.

Hemispherx settles Bioclones and Ribotech litigation

Hemispherx Biopharma has announced that all outstanding legal issues between Hemispherx and Bioclones and Ribotech have been resolved and that all litigation between the companies is in the process of being dismissed by mutual agreement.

Penwest initiates dosing in Phase Ia mitochondrial disease trial

Penwest Pharmaceuticals has initiated dosing in a Phase Ia clinical trial of A0001, a compound the company is developing for the treatment of symptoms associated with mitochondrial diseases.